May 2nd 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
Cardiology Month in Review: February 2024
March 4th 2024Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.
Experts' Perspectives: Top Issue Facing Cardiology in 2024
February 21st 2024This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.
Expert Panel Supports Intravascular Ultrasound Use in Peripheral Interventions
January 9th 2024A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.
Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH
September 15th 2023Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.
FDA Approves Updated Label for Mavacamten in Obstructive Hypertrophic Cardiomyopathy
June 16th 2023On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.
Analysis Predicts Obesity as Leading Risk Factor for Heart Attacks by 2050
June 8th 2023An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.
Immediate Complete Revascularization Non-Inferior to Staged Procedure in BIOVASC Trial
March 5th 2023In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.
Analysis Provides Updated Overview of Risk with Mitral Valve Repair for Mitral Regurgitation
January 20th 2023An analysis of data from the STS Adult Cardiac Surgery Database provides an updated overview of the risks of mortality, morbidity, and conversion-to-replacement among patients undergoing mitral valve repair for primary mitral regurgitation.
TAVI Associated with Lower Risk of Structural Valve Deterioration than Surgery
December 16th 2022An analysis of data from randomized clinical trials and non-randomized trials comparing TAVI and surgery provides an overview of 5-year incidence, outcomes, and predictors of structural valve deterioration with both approaches.
ACC and AHA Release Updated Guidance for Diagnosis and Management of Aortic Disease
November 3rd 2022Released on Nov. 2, the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease were created to be used concurrently with guidance published in 2020 and to replace previous guidance published in 2010 and 2015.